Profile data is unavailable for this security.
About the company
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
- Revenue in USD (TTM)552.74m
- Net income in USD-71.29m
- Incorporated1975
- Employees1.96k
- LocationInotiv Inc2701 Kent AveWEST LAFAYETTE 47906-1350United StatesUSA
- Phone+1 (317) 463-4527
- Fax+1 (765) 497-1102
- Websitehttps://www.inotivco.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 40.18m | 32.00 | -- | 2.39 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| BioXcel Therapeutics Inc | 1.76m | -153.05m | 40.53m | 74.00 | -- | -- | -- | 23.08 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| OncoCyte Corp | 1.38m | -40.66m | 40.90m | 43.00 | -- | 2.18 | -- | 29.59 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 41.65m | -- | -- | 4.00 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 41.77m | 12.00 | -- | 4.11 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Lipocine Inc | 4.71m | -8.97m | 41.87m | 17.00 | -- | 1.74 | -- | 8.89 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Clene Inc. | 620.00k | -48.81m | 42.05m | 82.00 | -- | 9.86 | -- | 67.82 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Kezar Life Sciences Inc | 7.00m | -101.87m | 42.16m | 58.00 | -- | 0.2247 | -- | 6.02 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Protara Therapeutics Inc | 0.00 | -42.47m | 43.24m | 26.00 | -- | 0.4111 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Dyadic International Inc | 2.26m | -7.85m | 43.27m | 7.00 | -- | 9.57 | -- | 19.19 | -0.2724 | -0.2724 | 0.0783 | 0.1547 | 0.1769 | -- | 4.51 | 322,197.20 | -61.58 | -36.82 | -73.50 | -39.85 | 38.24 | 22.47 | -348.00 | -410.16 | -- | -- | 0.5634 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Inotiv Inc | 552.74m | -71.29m | 43.63m | 1.96k | -- | 0.2101 | -- | 0.0789 | -2.77 | -2.77 | 21.44 | 8.00 | 0.6565 | 7.18 | 7.91 | 282,733.50 | -8.58 | -23.84 | -13.63 | -29.26 | 28.76 | 29.31 | -13.07 | -33.24 | 0.2744 | -0.1734 | 0.6476 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| NextCure Inc | 0.00 | -63.73m | 43.92m | 82.00 | -- | 0.4423 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Calcimedica Inc | 0.00 | -14.94m | 45.79m | 14.00 | -- | 2.65 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Lantern Pharma Inc | 0.00 | -17.53m | 46.16m | 21.00 | -- | 1.29 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Marker Therapeutics Inc | 3.32m | -12.21m | 46.29m | 8.00 | -- | 3.92 | -- | 13.94 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 46.88m | 17.00 | -- | 2.27 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Data as of Jul 03 2024. Currency figures normalised to Inotiv Inc's reporting currency: US Dollar USD
12.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.04m | 3.99% |
| Millennium Management LLCas of 31 Mar 2024 | 483.80k | 1.86% |
| Columbia Management Investment Advisers LLCas of 31 Mar 2024 | 449.16k | 1.73% |
| Kentucky Planning Partners LLCas of 31 Mar 2024 | 227.79k | 0.88% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 223.73k | 0.86% |
| Geode Capital Management LLCas of 31 Mar 2024 | 218.23k | 0.84% |
| Two Sigma Investments LPas of 31 Mar 2024 | 217.96k | 0.84% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 209.27k | 0.81% |
| Marshall Wace LLPas of 31 Mar 2024 | 153.38k | 0.59% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 148.11k | 0.57% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
